Clinical Trials Logo

Clinical Trial Details — Status: Temporarily not available

Administrative data

NCT number NCT02606929
Other study ID # HN1-2015
Secondary ID
Status Temporarily not available
Phase Phase 0
First received November 12, 2015
Last updated November 13, 2015
Start date January 2015
Est. completion date November 2015

Study information

Verified date November 2015
Source Università Popolare Homo & Natura
Contact n/a
Is FDA regulated No
Health authority Italy: The Italian Medicines Agency
Study type Expanded Access

Clinical Trial Summary

The purpose of this expanded access retrospective study is to determine whether tetracyclines, statins and antimycotics are effective in improvement of life and health condition in the treatment of multiple sclerosis due to autoimmune disease (MS) in all his forms, specially in patients that show no response to commonly used treatments


Description:

The purpose of this expanded access retrospective study is to determine whether tetracyclines, statins and antimycotics are effective in improvement of life and health condition in the treatment of multiple sclerosis due to autoimmune disease (MS) in all his forms.

The method of analysis chosen was the analysis of movement through the analysis of the mobility with the Barthel Index (disability evaluation) before and after treatment, the analysis of muscle imbalance Kendall before and after treatment and the final EDSS score.The treatment had a total duration of 45 days with three active principles subministration for 2 times a day, controlled nutrition, physiotherapy and gymnastics.

Considering the above, therefore, seems promising, also because of the low toxicity of the active, non immunosuppressant action and indeed exciting and synergistic action between them in the interests of recovery of homeostasis of the organism, the conduct of a suitable observational trial aimed at demonstrating the ability anti inflammatory and potentially reconstruction of damaged tissues, specially in patients that show no response to commonly used treatments


Recruitment information / eligibility

Status Temporarily not available
Enrollment 0
Est. completion date November 2015
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of Multiple Sclerosis

- EDSS score range from 3 to 7,5

Exclusion Criteria:

- Liver diseases: GOT GPT = 40

- Kidney diseases: Creatinine > 1,50

- Use of psychotropic drugs

- Other musculoskeletal diagnoses, unstable cardiovascular, respiratory, metabolic or other conditions that would interfere with this study

- Received a course of steroids (IV or oral) within 60 days of screening

Study Design

N/A


Related Conditions & MeSH terms

  • Autoimmune Diseases
  • Disseminated or Multiple Sclerosis Nos
  • Multiple Sclerosis
  • Multiple Sclerosis, Acute Relapsing
  • Multiple Sclerosis, Chronic Progressive
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Relapsing-Remitting
  • Sclerosis

Intervention

Drug:
Tetracycline - Statin - Antimycotic
every 12 hours, orally form

Locations

Country Name City State
Italy Centro Medico Forme di Bellezza Terni TR

Sponsors (1)

Lead Sponsor Collaborator
Università Popolare Homo & Natura

Country where clinical trial is conducted

Italy, 

See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4